Shots:

• The FDA has approved Imfinzi for an additional dosing option (1500mg- FD- q4w) in the approved indications of unresectable stage III NSCLC after CRT and prior treated advanced bladder cancer
• The approval is based on multiple studies- including the P-III PACIFIC study which supported the 2wks.- wt. based dosing in unresectable stage III NSCLC- and the P-III CASPIAN study which used 4wks. FD- during maintenance treatment in ES-SCLC
• The new dosing option for Imfinzi is under regulatory review in multiple countries- including in the EU where the new dosing option was granted accelerated assessment

 ­ Ref: AstraZeneca | Image: Mint